# T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

> **NCT06478251** · PHASE1 · RECRUITING · sponsor: **TingBo Liang** · enrollment: 9 (estimated)

## Conditions studied

- Tumor, Solid

## Interventions

- **DRUG:** NW-301V
- **DRUG:** NW-301D

## Key facts

- **NCT ID:** NCT06478251
- **Lead sponsor:** TingBo Liang
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06478251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06478251, "T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06478251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*